Dr. Fizazi began by revisiting the role of docetaxel in the mHSPC setting, emphasizing that treatment benefit varies ...
Significant improvement in radiographic progression-free survival seen first in BRCA subgroup. HealthDay News — For patients with metastatic castration-sensitive prostate cancer (mCSPC) with ...
HRR mutations are commonly of germline origin, with several real world studies suggesting a 23-44% probability of an HRR alteration to be of germline origin: 1 The following summarizes recommendations ...
A powerful new drug combination—niraparib added to standard prostate cancer therapy—has been shown to significantly delay disease progression in men with specific DNA repair gene mutations. In the ...
Niraparib and abiraterone acetate regimen demonstrates clinically meaningful delay in disease progression, nearly halving the risk of progression or death, with an early trend toward improved overall ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results